COMMUNIQUÉS West-GlobeNewswire
-
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
17/03/2026 -
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
17/03/2026 -
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
17/03/2026 -
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
17/03/2026 -
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
17/03/2026 -
Axe Compute Appoints Two Technology and Telecom Luminaries to Board of Directors as Company Accelerates AI Infrastructure Strategy
17/03/2026 -
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
17/03/2026 -
Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
17/03/2026 -
Former Peloton and Equinox Design Leader Cecilia Farooqi Joins Noom as Head of Product Design
17/03/2026 -
ReFocus Eye Health Expands Presence Through Strategic Affiliation with Seven Partner Practices and Four Ambulatory Surgery Centers
17/03/2026 -
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
17/03/2026 -
Center for Radiology Education Launches Nationwide Initiative to Provide Medical Imaging Scholarships at John Patrick University
17/03/2026 -
Microbot Medical® to Participate at the 38th Annual Roth Conference
17/03/2026 -
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
17/03/2026 -
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
17/03/2026 -
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
17/03/2026 -
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
17/03/2026 -
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
17/03/2026 -
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
17/03/2026
Pages